摘要
Infection with the severe acute respiratory syndrome novel type-2 novel coronavirus (SARS-CoV-2) responsible for the 2019 coronavirus disease (CO<span style="font-family:;" "="">VID-19) shows a highly heterogeneous clinical presentation and age affliction in children and adults, ranging from asymptomatic or mild disease to severe inv<span>olvement, with potentially fatal respiratory failure and multiple organ dysfunction. As susceptibility to severe COVID-19 depends upon comorbid factors including immune competence, optimizing the latter through low-dose supplementation or high dose treatment with immune globulin therapy in those with primary immune deficiency and post-infectiou</span>s immune sequelae of SARS-CoV-2 and existing autoimmune disorders is essential. There are no existing guidelines hence;this paper provides a framework for considering preliminary guidelines for the use of immune globulin therapy during COVID-19.</span>
Infection with the severe acute respiratory syndrome novel type-2 novel coronavirus (SARS-CoV-2) responsible for the 2019 coronavirus disease (CO<span style="font-family:;" "="">VID-19) shows a highly heterogeneous clinical presentation and age affliction in children and adults, ranging from asymptomatic or mild disease to severe inv<span>olvement, with potentially fatal respiratory failure and multiple organ dysfunction. As susceptibility to severe COVID-19 depends upon comorbid factors including immune competence, optimizing the latter through low-dose supplementation or high dose treatment with immune globulin therapy in those with primary immune deficiency and post-infectiou</span>s immune sequelae of SARS-CoV-2 and existing autoimmune disorders is essential. There are no existing guidelines hence;this paper provides a framework for considering preliminary guidelines for the use of immune globulin therapy during COVID-19.</span>
作者
David S. Younger
David S. Younger(School of Medicine, Department of Medicine, Division of Neuroscience, Graduate School of Public Health, Department of Health Pol-icy and Management, City University of New York (CUNY), New York, USA)
